Fresenius forecasts 2020 sales growth driven by drug, dialysis units
Reuters
Published Feb 20, 2020 06:16
Fresenius forecasts 2020 sales growth driven by drug, dialysis units
(Reuters) - German healthcare group Fresenius (DE:FREG) forecast 2020 revenue growth on Thursday, saying growth of its infusion drugs unit in emerging markets partially offset softer development in North America in the fourth quarter and noting strong growth of its dialysis business.
Fresenius' fourth-quarter adjusted operating income came in at 1.29 billion euros (£1.07 billion), slightly above the 1.25 billion euros expected on average by analysts according to a company-provided consensus.
The 2020 guidance does not include any effects from the coronavirus outbreak because it is too early to quantify those, Fresenius said, adding it did not currently expect a significant negative financial impact.
The group said it expected its sales to grow between 4% and 7% in 2020 and net income to grow between 1% and 5% in constant currency.
Fresenius also confirmed its mid-term targets, saying it expects its sales growth and efficiency improvement initiatives as well as the drug unit's biosimilars business to drive an acceleration of group earnings growth over 2020-2023.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.